3.50
+0.02(+0.57%)
Currency In USD
| Previous Close | 3.48 |
| Open | 3.51 |
| Day High | 3.58 |
| Day Low | 3.43 |
| 52-Week High | 13.5 |
| 52-Week Low | 2.76 |
| Volume | 478,055 |
| Average Volume | 811,738 |
| Market Cap | 361.16M |
| PE | -0.31 |
| EPS | -11.24 |
| Moving Average 50 Days | 3.91 |
| Moving Average 200 Days | 7.01 |
| Change | 0.02 |
If you invested $1000 in Alumis Inc. Common Stock (ALMS) since IPO date, it would be worth $263.16 as of July 10, 2025 at a share price of $3.5. Whereas If you bought $1000 worth of Alumis Inc. Common Stock (ALMS) shares 1 year ago, it would be worth $263.16 as of July 10, 2025 at a share price of $3.5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Alumis to Present at the Jefferies Global Healthcare Investor Conference
GlobeNewswire Inc.
May 29, 2025 8:15 PM GMT
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, P
Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis
GlobeNewswire Inc.
May 29, 2025 11:55 AM GMT
-Topline readout expected in early Q1 2026-SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated dise
Alumis Completes Merger with ACELYRIN
GlobeNewswire Inc.
May 21, 2025 1:10 PM GMT
Establishes leading clinical stage biopharma company with differentiated portfolio of therapies and strong balance sheetSOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company develop